Human Genome Sciences Inc. of Rockville is to receive $40 million next month from Swiss pharma giant Novartis for completing a phase 2b trial of Albuferon. The drug is used to treat chronic hepatitis C, a viral liver disease.
Read More...
[Source: Yahoo! News Search Results for liver disease help]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment